When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
In a report published in Science Robotics, researchers claim to have created microrobots that can successfully traverse the blood-brain barrier in mice. The team from Harbin Institute of…
What are the latest treatment options for patients with #AML? @manosnikolousis discusses treatment options with a clinical nurse specialist and a patient with AML.
